AVERAGE WEEKLY GAIN: 70.75%
Here’s a quick recap of how this week’s Buzz Stocks fared:
June 21th, 2010: Shares of EF Johnson Technologies, Inc. (Nasdaq: EFJI) rose 40 percent from last Friday’s close in morning trading on Monday after the company increased its sale price 42 percent. The company will now be acquired by Francisco Partners, an affiliate of a private equity firm for $1.50 per share in cash, up from $1.05 per share.
Up as much as 40% since our post.
June 22th, 2010: EnteroMedics, Inc. (Nasdaq: ETRM) was our biggest gainer of the week. Shares opened at $0.31 on Tuesday, and climbed nearly 53 percent to a close of $0.61 after the company announced positive data from its obesity treatment device. The following day, shares soared to $0.81, before settling back down to a closing price of $0.63.
Up as much as 125% since our post.
June 23th, 2010: Lightbridge Corp. (Nasdaq: LTBR) shares were up 50 percent on Wendesday after the nuclear fuel technology developer announced “a major technological breakthrough,” based on a proprietary all-metal fuel assembly design could reduce both initial capital costs per megawatt and annual operating costs per kilowatt-hour of nuclear power. According to a recent news release, this breakthrough makes nuclear power more competitive with other forms of electricity generation while contributing to a significant reduction of CO2 emissions.
Up as much as 69% since our post.
June 24th, 2010: Molecular Insight Pharmaceuticals, Inc. (Nasdaq: MIPI) was first featured as a Buzz Stock of the Day on June 18th after shares rose 30 percent from the previous day’s close, about a week after the company presented nonclinical data demonstrating the utility of the Company’s novel radiopharmaceutical compounds for the molecular imaging of prostate and other tumors. Less than a week later, shares surged 65 percent from Wednesday’s closing price of $1.60, trading at at a high of $2.64 on Thursday after Molecular Insight Pharmaceuticals, Inc. announced positive data from a completed Phase 2a clinical study of Azedra™, the Company’s lead oncology therapeutic for a common childhood cancer.